Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1359104519853849 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The risk of donor-acquired allergy in solid organ transplant recipients: a systematic review.
Ann Allergy Asthma Immunol
January 2025
Center for Drug Safety and Immunology, Vanderbilt University Medical Centre, Nashville, Tennessee, USA; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Background: Donor acquired allergy (DAA) occurs when donors transfer their allergies to recipients through solid organ transplant (SOT). However, the risk of DAA in recipients of organs from allergic donors has not been systematically characterized.
Objective: We sought to synthesize the available evidence on the risk of DAA in SOT recipients.
Establishment and Evaluation of Rabbit Model for Corneal Ectasia by Photorefractive Keratectomy.
Exp Eye Res
January 2025
Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
The study aimed to compare the effects of different types of excimer laser keratectomy on rabbit corneas and to identify the optimal disease model for corneal ectasia. Additionally, investigating the structural and molecular alterations in the novel disease model helped explore the mechanisms underlying biomechanical cues in corneal ectasia. 2.
View Article and Find Full Text PDFPituitary adenomas: biology, nomenclature and clinical classification.
Rev Endocr Metab Disord
January 2025
Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
An 'adenoma' is a benign neoplasm composed of epithelial tissue, and has been standard nomenclature for primary pituitary neoplasms. In 2022, the fifth edition of the WHO Classification of Endocrine Tumours and of Central Nervous System Tumours, renamed pituitary adenomas as neuroendocrine tumours (NETs), assigning an oncology label to pituitary invariably benign neoplasms. Multidisciplinary workshops convened by the Pituitary Society have questioned the process, validity, and merit of this arbitrary change, while addressing the adverse clinical implications of the proposed new nomenclature.
View Article and Find Full Text PDFEffect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers.
Pharmaceutics
January 2025
Medical Faculty Heidelberg, Heidelberg University, 69117 Heidelberg, Germany.
: Bempedoic acid (BA) is a novel cholesterol-lowering agent with proven positive effects on cardiovascular endpoints. Because it is an inhibitor of the hepatic transporters OATP1B1 and OATP1B3, two uptake transporters regulating the intrahepatic availability of statins, it increases the systemic exposure of co-administered statins. This interaction could raise the risk of myopathy.
View Article and Find Full Text PDFSafety and Intranasal Retention of a Broad-Spectrum Anti-SARS-CoV-2 Monoclonal Antibody SA55 Nasal Spray in Healthy Volunteers: A Phase I Clinical Trial.
Pharmaceutics
December 2024
Phase I Clinical Trial Unit, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Background: A broad-spectrum anti-SARS-CoV-2 monoclonal antibody (mAb), SA55, is highly effective against SARS-CoV-2 variants. This trial aimed at demonstrating the safety, tolerability, local drug retention and neutralizing activity, systemic exposure level, and immunogenicity of the SA55 nasal spray in healthy individuals.
Methods: This phase I, dose-escalation clinical trial combined an open-label design with a randomized, controlled, double-blind design.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!